NSE level in combined neuroendocrine and adenocarcinoma EGFR mutated lung cancer resistant to EGFR-TKI

被引：6
|
作者：
Facchinetti, Francesco [1 ]
Tiseo, Marcello [1 ]
Gnetti, Letizia [2 ]
Silini, Enrico Maria [2 ]
Ardizzoni, Andrea [1 ]
机构：
[1] Univ Hosp Parma, Med Oncol Unit, I-43100 Parma, Italy
[2] Univ Hosp Parma, Surg Pathol Unit, I-43100 Parma, Italy
来源：
LUNG CANCER | 2013年 / 82卷 / 01期
关键词：
CARCINOMA;
D O I：
10.1016/j.lungcan.2013.07.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：177 / 178
页数：2
相关论文
共 50 条
  • [1] Overcoming EGFR-TKI resistance in EGFR-mutated lung cancer
    Gardizi, M.
    Scheffler, M.
    Bos, M.
    Geist, T.
    Heukamp, L.
    Nogova, L.
    Toepelt, K.
    Fernandez-Cuesta, L.
    Culmann, H.
    Kaminsky, B.
    Panse, J.
    Becker, C.
    Mattonet, C.
    Serke, M.
    Schmitz, S.
    Schnell, R.
    Galetke, W.
    Hekmat, K.
    Buettner, R.
    Wolf, J.
    ONKOLOGIE, 2013, 36 : 30 - 30
  • [2] Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma
    Mao, Xiaowei
    Liu, Jiabing
    Hu, Fang
    Niu, Yanjie
    Pan, Feng
    Fu, Xiaolong
    Jiang, Liyan
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 1293 - 1302
  • [3] Outcomes of EGFR-TKI therapy in EGFR mutated metastatic lung adenocarcinoma in an inner city population
    Thekkekara, Romy Jose
    Kumar, Rohit
    Lad, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] EGFR-TKI FOR LUNG CANCER
    Bai, Chunxue
    RESPIROLOGY, 2010, 15 : 23 - 23
  • [5] Different first line EGFR-TKI regimen and the clearance of EGFR sensitive mutation in acquired EGFR-TKI resistant lung adenocarcinoma patients
    Zhuang, W.
    Xu, C.
    Wang, W.
    Song, Z.
    Zhu, Y.
    Chen, R.
    Guan, Y.
    Yi, X.
    Fang, M.
    Chen, G.
    Lv, T.
    Song, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Pemetrexed combined with cisplatin for patients with EGFR-TKI resistant advanced lung cancer
    Zhou, Zunyan
    Yang, Jiyuan
    Li, Hongtao
    Luo, Fei
    Shao, Chengze
    Wang, Qian
    Du, Wei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (07): : 8678 - 8685
  • [7] TARGETING THE HIPPO EFFECTOR YAP OVERCOMES THE RESISTANCE TO EGFR-TKI OF BOTH EGFR MUTATED AND KRAS MUTATED LUNG ADENOCARCINOMA
    Chung, Chaeuk
    Park, Dongil
    Kim, Ju Ock
    Park, Hee Sun
    Lee, Jeong Eun
    Moon, Jae Young
    Lim, Daesik
    Lee, Jaechul
    RESPIROLOGY, 2015, 20 : 102 - 102
  • [8] RELEVANCE BETWEEN CEA LEVEL AND EGFR MUTATION, EFFICACY OF EGFR-TKI IN PATIENTS WITH LUNG ADENOCARCINOMA
    Zhang, Wei Y.
    Han, Hui B.
    Jin, Bo
    Shao, Hua M.
    Dong, Yu
    Huang, Mi A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S891 - S891
  • [9] EGFR-TKI FOR EGFR MUTATED NSCLC: NEW EVIDENCE
    Okamoto, I.
    ANNALS OF ONCOLOGY, 2010, 21 : 40 - 40
  • [10] EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
    Gu, Weiguang
    Zhang, Hua
    Lu, Yiyu
    Li, Minjing
    Yang, Shuang
    Liang, Jianmiao
    Ye, Zhijian
    Li, Zhihua
    He, Minhong
    Shi, Xiaoliang
    Wang, Fei
    You, Dong
    Gu, Weiquan
    Feng, Weineng
    CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 841 - 850
12345